**RESULTS:** Overall, RPX9 restored the activity of β-lactams against 92.3, 96.7, 100.0 and 100.0% of all β-lactamase-positive strains. RPX9 alone was highly active (MIC ≤ 0.5 µg/mL) against 99.4% of the isolates. RPX7009 alone was highly active (MIC ≤ 0.06 µg/mL) against 98.8% of the isolates.

**CONCLUSIONS:** Our study demonstrated that β-lactamase inhibitors have the potential to restore the activity of β-lactams against β-lactamase-positive strains. The combination of RPX9 and RPX7009 with β-lactams is a promising strategy for the treatment of infections caused by β-lactamase-positive strains.